drugset / Trial / NCT00358475

Study Of Perennial Allergic Rhinitis

NCT00358475

Phase 3 Completed 65 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc. Typical symptoms are sneezing, nasal congestion and pruritus and rhinorrhea.

Timeline

Start
2005-06-21
Primary completion
2005-10-01
Completion
2005-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GW685698 Unknown Intranasal